Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.

@article{Nanus2004ActiveCF,
  title={Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma.},
  author={David M. Nanus and Alexandria Mary Garino and Matthew Ivan Milowsky and Maureen M Larkin and Janice P Dutcher},
  journal={Cancer},
  year={2004},
  volume={101 7},
  pages={
          1545-51
        }
}
BACKGROUND Immunotherapy is generally ineffective in patients with sarcomatoid renal cell carcinoma (RCC) and in patients with rapidly progressive metastatic or locally recurrent disease, with a median time to progression of approximately 2 months and a median survival of 4-7 months. Gemcitabine-based regimens have modest antitumor activity, whereas doxorubicin is often used to treat sarcomatoid RCC. Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 67 CITATIONS, ESTIMATED 33% COVERAGE

Clinicopathologic characteristics and prognostic factors of sarcomatoid renal cell carcinoma

  • Journal of Cancer Research and Clinical Oncology
  • 2014
VIEW 2 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Prognostic factors of metastatic renal cell carcinoma with extensive sarcomatoid component

  • Journal of Cancer Research and Clinical Oncology
  • 2013
VIEW 6 EXCERPTS
CITES RESULTS & BACKGROUND
HIGHLY INFLUENCED

Management of advanced kidney cancer: Canadian Kidney Cancer Forum (CKCF) consensus update 2017.

  • Canadian Urological Association journal = Journal de l'Association des urologues du Canada
  • 2017

FILTER CITATIONS BY YEAR

2004
2017

CITATION STATISTICS

  • 5 Highly Influenced Citations

  • Averaged 2 Citations per year over the last 3 years